FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385457079> ?p ?o ?g. }

• W4385457079 abstract "Pyroptosis is a form of pro-inflammatory cell death that can be mediated by gasdermin D (GSDMD) activation induced by inflammatory caspases such as caspase-1. Emerging evidence suggests that targeting GSDMD activation or pyroptosis may facilitate the reduction of vascular inflammation and atherosclerotic lesion development. The current study investigated the therapeutic effects of inhibition of GSDMD activation by the novel GSDMD inhibitor N-Benzyloxycarbonyl-Leu-Leu-Ser-Asp(OMe)-fluoromethylketone (Z-LLSD-FMK), the specific caspase-1 inhibitor N-Benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone (Z-YVAD-FMK), and a combination of both on atherosclerosis in ApoE-/- mice fed a western diet at 5 weeks of age, and further determined the efficacy of these polypeptide inhibitors in bone marrow-derived macrophages (BMDMs). In vivo studies there was plaque formation, GSDMD activation, and caspase-1 activation in aortas, which increased gradually from 6 to 18 weeks of age, and increased markedly at 14 and 18 weeks of age. ApoE-/- mice were administered Z-LLSD-FMK (200 µg/day), Z-YVAD-FMK (200 µg/day), a combination of both, or vehicle control intraperitoneally from 14 to 18 weeks of age. Treatment significantly reduced lesion formation, macrophage infiltration in lesions, protein levels of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1, and pyroptosis-related proteins such as activated caspase-1, activated GSDMD, cleaved interleukin(IL)-1β, and high mobility group box 1 in aortas. No overt differences in plasma lipid contents were detected. In vitro treatment with these polypeptide inhibitors dramatically decreased the percentage of propidium iodide-positive BMDMs, the release of lactate dehydrogenase and IL-1β, and protein levels of pyroptosis-related proteins both in supernatants and cell lysates elevated by lipopolysaccharide + nigericin. Notably however, there were no significant differences in the above-mentioned results between the Z-LLSD-FMK group and the Z-YVAD-FMK group, and the combination of both did not yield enhanced effects. These findings indicate that suppression of GSDMD activation by Z-LLSD-FMK or Z-YVAD-FMK reduces vascular inflammation and lesion development in ApoE-/- mice." @default.
• W4385457079 created "2023-08-02" @default.
• W4385457079 creator A5002518943 @default.
• W4385457079 creator A5005105854 @default.
• W4385457079 creator A5013939729 @default.
• W4385457079 creator A5018123536 @default.
• W4385457079 creator A5022128403 @default.
• W4385457079 creator A5030085195 @default.
• W4385457079 creator A5038939879 @default.
• W4385457079 creator A5048609057 @default.
• W4385457079 creator A5053743858 @default.
• W4385457079 date "2023-08-01" @default.
• W4385457079 modified "2023-09-22" @default.
• W4385457079 title "Inhibition of GSDMD activation by Z-LLSD-FMK or Z-YVAD-FMK reduces vascular inflammation and atherosclerotic lesion development in ApoE−/− mice" @default.
• W4385457079 cites W1638567831 @default.
• W4385457079 cites W1864325817 @default.
• W4385457079 cites W1882905539 @default.
• W4385457079 cites W1972483153 @default.
• W4385457079 cites W1973351162 @default.
• W4385457079 cites W1983210498 @default.
• W4385457079 cites W1991274029 @default.
• W4385457079 cites W1994701170 @default.
• W4385457079 cites W2010520310 @default.
• W4385457079 cites W2024591203 @default.
• W4385457079 cites W2054260525 @default.
• W4385457079 cites W2070734764 @default.
• W4385457079 cites W2081859430 @default.
• W4385457079 cites W2082078082 @default.
• W4385457079 cites W2098691880 @default.
• W4385457079 cites W2100748836 @default.
• W4385457079 cites W2121075882 @default.
• W4385457079 cites W2122826329 @default.
• W4385457079 cites W2128706959 @default.
• W4385457079 cites W2132430680 @default.
• W4385457079 cites W2143102054 @default.
• W4385457079 cites W2147627101 @default.
• W4385457079 cites W2171487873 @default.
• W4385457079 cites W2175794645 @default.
• W4385457079 cites W2268997463 @default.
• W4385457079 cites W2395774853 @default.
• W4385457079 cites W2461756806 @default.
• W4385457079 cites W2528617117 @default.
• W4385457079 cites W2531064413 @default.
• W4385457079 cites W2560541542 @default.
• W4385457079 cites W2595134102 @default.
• W4385457079 cites W2724823461 @default.
• W4385457079 cites W2748400555 @default.
• W4385457079 cites W2768102094 @default.
• W4385457079 cites W2808365021 @default.
• W4385457079 cites W2895086405 @default.
• W4385457079 cites W2920248606 @default.
• W4385457079 cites W2925078913 @default.
• W4385457079 cites W2972470504 @default.
• W4385457079 cites W2983652778 @default.
• W4385457079 cites W2988988674 @default.
• W4385457079 cites W2991926819 @default.
• W4385457079 cites W3003299879 @default.
• W4385457079 cites W3004159905 @default.
• W4385457079 cites W3004399337 @default.
• W4385457079 cites W3022981886 @default.
• W4385457079 cites W3036343652 @default.
• W4385457079 cites W3085463956 @default.
• W4385457079 cites W3122515325 @default.
• W4385457079 cites W3139070968 @default.
• W4385457079 cites W3155824129 @default.
• W4385457079 cites W3158874774 @default.
• W4385457079 cites W3163123861 @default.
• W4385457079 cites W3164224307 @default.
• W4385457079 cites W3185944309 @default.
• W4385457079 cites W3196909673 @default.
• W4385457079 cites W3215114513 @default.
• W4385457079 cites W4220680027 @default.
• W4385457079 cites W4229038593 @default.
• W4385457079 cites W4232748180 @default.
• W4385457079 cites W4300042626 @default.
• W4385457079 doi "https://doi.org/10.3389/fphar.2023.1184588" @default.
• W4385457079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37593179" @default.
• W4385457079 hasPublicationYear "2023" @default.
• W4385457079 type Work @default.
• W4385457079 citedByCount "0" @default.
• W4385457079 crossrefType "journal-article" @default.
• W4385457079 hasAuthorship W4385457079A5002518943 @default.
• W4385457079 hasAuthorship W4385457079A5005105854 @default.
• W4385457079 hasAuthorship W4385457079A5013939729 @default.
• W4385457079 hasAuthorship W4385457079A5018123536 @default.
• W4385457079 hasAuthorship W4385457079A5022128403 @default.
• W4385457079 hasAuthorship W4385457079A5030085195 @default.
• W4385457079 hasAuthorship W4385457079A5038939879 @default.
• W4385457079 hasAuthorship W4385457079A5048609057 @default.
• W4385457079 hasAuthorship W4385457079A5053743858 @default.
• W4385457079 hasBestOaLocation W43854570791 @default.
• W4385457079 hasConcept C139964883 @default.
• W4385457079 hasConcept C164027704 @default.
• W4385457079 hasConcept C17172800 @default.
• W4385457079 hasConcept C185592680 @default.
• W4385457079 hasConcept C190283241 @default.
• W4385457079 hasConcept C202751555 @default.
• W4385457079 hasConcept C203014093 @default.
• W4385457079 hasConcept C2776914184 @default.
• W4385457079 hasConcept C2777209026 @default.

• next